Franz-Werner Haas, CureVac CEO (Christoph Schmidt/picture-alliance/dpa/AP Images)
GSK, CureVac forge ahead with mid-stage plans for flu, Covid mRNA vaccines
GSK-partnered mRNA biotech CureVac released interim Phase I data on its new mRNA vaccines for Covid and the flu, causing its stock $CVAC to jump …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
